Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LOSS PER SHARE

LOSS PER SHARE

3 Months Ended

Dec. 31, 2015

8.	LOSS PER SHARE

In accordance with ASC 260-10 (formerly SFAS 128, Computation of Earnings Per Share), basic net income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. For the three months ended December 31, 2015 and 2014, the Company has excluded all common equivalent shares from the calculation of diluted net loss per share as such securities are anti-dilutive.

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended December 31, 2015 and 2014 is as follows:

	Three months ended December 31,
	2015			2014
Net Loss for computation of basic and diluted net loss per share:
From continuing operations	$	(3,449,500	)	$	(873,700	)
From discontinued operations		(1,800	)		(900	)
Net loss	$	(3,451,300	)	$	(874,600	)
Basic and Diluted net loss per share:
From continuing operations	$	(0.03	)	$	(0.01	)
From discontinued operations		(0.00	)		(0.00	)
Basic net loss per share	$	(0.03	)	$	(0.01	)

Basic and Diluted weighted average shares outstanding		102,417,409			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		63,196,467			1,650,000
Warrants		6,856,792			939,404
Options		14,230,011			12,417,499